SREBF2 and hepatocellular carcinoma: Research has indicated that SREBF2 facilitates the transcriptional activation of STARD4, thereby enhancing STARD4-mediated cholesterol transport, a process deemed critical for SREBF2-induced sorafenib resistance in HCC [22].